OncoMatch/Clinical Trials/NCT06544720
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Is NCT06544720 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies SCG142 TCR-T cells for human papillomavirus associated carcinomas.
Treatment: SCG142 TCR-T cells — A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cervical Cancer
Penile Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06544720 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages